Valuation: Ionis Pharmaceuticals, Inc.

Capitalization 1.24TCr 1.05TCr 976.33Cr 918.24Cr 1.71TCr 1,12500Cr 1.83TCr 11TCr 4.45TCr 54TCr 4.64TCr 4.54TCr 1,95300Cr P/E ratio 2025 *
-33.7x
P/E ratio 2026 * -25.2x
Enterprise value 1.14TCr 973.15Cr 901.67Cr 848.01Cr 1.58TCr 1,03900Cr 1.69TCr 10TCr 4.11TCr 49TCr 4.28TCr 4.19TCr 1,80300Cr EV / Sales 2025 *
12.7x
EV / Sales 2026 * 12.7x
Free-Float
99.23%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.48%
1 week-3.32%
Current month-2.87%
1 month-5.53%
3 months+4.47%
6 months+84.93%
Current year-2.87%
More quotes
1 week 74.2
Extreme 74.2
79.75
1 month 74.2
Extreme 74.2
86.15
Current year 74.2
Extreme 74.2
86.15
1 year 23.95
Extreme 23.95
86.15
3 years 23.95
Extreme 23.95
86.15
5 years 23.95
Extreme 23.95
86.15
10 years 19.59
Extreme 19.5927
86.58
More quotes
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 71 01/09/2000
Director/Board Member 81 01/01/1994
Director/Board Member 64 13/12/2005
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.48%-3.32%+135.13%+88.52% 1.24TCr
-0.44%-3.92%-3.48%+11.03% 4.81TCr
-1.25%-2.72%+14.25%+5.09% 4.05TCr
-1.25%-4.94%+52.59%+25.26% 3.74TCr
-0.71%-3.69%+20.76%+39.16% 3.07TCr
-3.91%-3.34%+188.70%+321.29% 2.33TCr
-0.79%-0.18%+74.76%+165.05% 1.72TCr
Average -1.00%-1.23%+68.96%+93.63% 2.99TCr
Weighted average by Cap. -1.11%-1.43%+49.44%+68.20%
See all sector performances

Financials

2025 *2026 *
Net sales 90Cr 76Cr 71Cr 67Cr 123.99Cr 8.16TCr 133.01Cr 817.58Cr 323Cr 3.88TCr 336.35Cr 329.45Cr 14TCr 92Cr 78Cr 72Cr 68Cr 126.56Cr 8.33TCr 135.76Cr 834.53Cr 329.7Cr 3.96TCr 343.32Cr 336.28Cr 14TCr
Net income -36Cr -30Cr -28Cr -26Cr -49Cr -3.24TCr -53Cr -324.49Cr -128.2Cr -1.54TCr -133.49Cr -130.76Cr -5.62TCr -49Cr -42Cr -39Cr -36Cr -68Cr -4.45TCr -72Cr -445.45Cr -175.98Cr -2.11TCr -183.26Cr -179.5Cr -7.72TCr
Net Debt -95Cr -81Cr -75Cr -70Cr -130.71Cr -8.61TCr -140.21Cr -861.89Cr -340.5Cr -4.09TCr -354.57Cr -347.3Cr -15TCr -75Cr -64Cr -59Cr -56Cr -103.31Cr -6.8TCr -110.81Cr -681.18Cr -269.11Cr -3.23TCr -280.23Cr -274.48Cr -12TCr
More financial data * Estimated data
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Employees
1,069
More about the company
Date Price Change Volume
21/26/21 76.88 $ +0.71% 29,82,709
16/26/16 76.33 $ -1.14% 30,00,587
15/26/15 77.21 $ -2.10% 14,09,021
14/26/14 78.87 $ -0.77% 21,21,498
13/26/13 79.48 $ -2.67% 18,85,179

Delayed Quote Nasdaq, January 21, 2026 at 12:42 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
76.33USD
Average target price
90.63USD
Spread / Average Target
+18.73%
Consensus

Quarterly revenue - Rate of surprise